Skip to content

HARIDRADYA LEHA WITH URSODEOXYCHOLIC ACID IN KAMALA (HEPATOCELLULAR JAUNDICE)

TO COMPARE EFFICACY OF HARIDRADYA LEHA WITH URSODEOXYCHOLIC ACID IN KAMALA (HEPATOCELLULAR JAUNDICE) -A RANDOMISED CONTROLLED CLINICAL TRIAL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031835
Enrollment
60
Registered
2021-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: HARIDRADYA LEHA: Curcuma longa 1 part Berberis aristata 1 part Terminalia chebula 1 part Terminalia bellerica 1 part Embelica officicnalis 1 part Picorrhiza Kurroa 1 part Lauha Bhasma 1

Sponsors

ALL INDIA INSTITUTE OF AYURVEDA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Diagnosed by elevated bilirubin (Conjugated) in liver function test >1.2 mg/dl(17 micro mol/L) to 15 mg/dl with altered liver function test 2) Age :18-50 3) Sex ; either male or female 4) Haridratwak,netra,nakha,anana(Greenish yellow discolouration of skin,sclera ,nails and buccal mucosa) 5) Raktapeetasakrutmutra(Reddish yellow faecal matter and urine) 6) Daha (Burning sensation) 7) Avipaka(Indigestion) 8) Dourbalya (Lethargy) 9) Sadana (Fatigue) 10) Aruchi (Loss of taste)

Exclusion criteria

Exclusion criteria: 1) Pregnancy 2) Obstructive jaundice 3) Auto immune hepatitis 4) Hepatocellular Carcinoma 5) Liver Transplantation or Any other Condition Interfering with the result of the treatment. 6) Thalassemia major, Sickle cell Disease other haemolytic Jaundices 7) Ca -head of pancreas 8) Gilbertâ??s Syndrome 9) Patients having history of Chronic HTN&DM

Design outcomes

Primary

MeasureTime frame
REDUCTION IN ELEVATED BILIRUBIN ALONG WITH L.F.T.CHANGES IN CLINICAL PRESENTATIONTimepoint: 0th day, after completion of treatment i.e. 30th day, and during follow up

Secondary

MeasureTime frame
Overall improvement in the quality of lifeTimepoint: 0th day, after completion of treatment i.e. 30th day, and during follow up

Countries

India

Contacts

Public ContactDR RAMA KANT YADAVA

ALL INDIA INSTITUTE OF AYURVEDA

drrky68@gmail.com9412148437

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026